Literature DB >> 17691114

Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer.

Laura Strauss1, Christoph Bergmann, Theresa L Whiteside.   

Abstract

Circulating human CD4(+)CD25(high)Foxp3(+) T cell populations (Treg) may contain activated CD4(+)CD25(+) T cells interfering with Treg evaluation. To gain insights into the phenotypic and functional characteristics of Treg in patients with cancer, we have analyzed CD4(+)CD25(high) populations at the clonal level. Single-cell sorted (SCS) CD4(+)CD25(high) T cells obtained from PBMC of normal controls (NC) or patients with squamous cell carcinoma of the head and neck (HNSCC) were plated at 1 cell/well in 96 well plates and expanded with anti-CD3/anti-CD28 Abs and 1,000 IU IL-2/mL in the presence or absence of rapamycin (1 nM). All generated clones were evaluated for the phenotype by flow cyometry and suppressor function in CFSE-based proliferation assays. Clones had heterogeneous CD25 expression levels. Cloning efficiency of CD4(+)CD25(high) T cells was low. CD25(high) clones expressed CTLA-4, Foxp3, CD62L, but little GITR and suppressed proliferation of autologous CD4(+)CD25(-) responder cells. Clones of activated CD4(+)CD25(interm./low) cells expressed intermediate to high levels of GITR and HLA-DR and did not suppress proliferation of responder cells. The number, suppressor phenotype and function of CD25(high) Treg clones were significantly enhanced in HNSCC patients relative to NC (p </= 0.001). CD4(+)CD25(+) populations comprise phenotypically and functionally distinct subsets of CD25(+) cells. Only a small fraction of these activated CD4(+) T cells are potent suppressor cells characterized by high expression levels of CD25, Foxp3, CTLA-4 and CD62L. The number of expandable Treg is increased in HNSCC patients. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17691114     DOI: 10.1002/ijc.23001

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Authors:  Carlos A Ramos; Neeharika Narala; Gayatri M Vyas; Ann M Leen; Ulrike Gerdemann; Erich M Sturgis; Matthew L Anderson; Barbara Savoldo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

Review 2.  Immunology and Immunotherapy of Head and Neck Cancer.

Authors:  Robert L Ferris
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

3.  Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.

Authors:  Sanjib Chaudhary; Koelina Ganguly; Sakthivel Muniyan; Ramesh Pothuraju; Zafar Sayed; Dwight T Jones; Surinder K Batra; Muzafar A Macha
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

Review 4.  What are regulatory T cells (Treg) regulating in cancer and why?

Authors:  Theresa L Whiteside
Journal:  Semin Cancer Biol       Date:  2012-03-28       Impact factor: 15.707

5.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 6.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

Review 7.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

8.  T regulatory cell markers in oral squamous cell carcinoma: Relationship with survival and tumor aggressiveness.

Authors:  Geane Moreira; Lívia Bonfim Fulgêncio; Elismauro Francisco DE Mendonça; Cláudio Rodrigues Leles; Aline Carvalho Batista; Tarcília Aparecida DA Silva
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 9.  Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?

Authors:  Henry Yim Wu
Journal:  Clin Immunol       Date:  2008-10-19       Impact factor: 3.969

Review 10.  Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Authors:  Ulf Petrausch; Christian H Poehlein; Shawn M Jensen; Chris Twitty; James A Thompson; Ilka Assmann; Sachin Puri; Michael G LaCelle; Tarsem Moudgil; Levi Maston; Kevin Friedman; Sarah Church; Elisa Cardenas; Daniel P Haley; Edwin B Walker; Emmanuel Akporiaye; Andrew D Weinberg; Sidney Rosenheim; Todd S Crocenzi; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Bernard A Fox
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.